ARRO-CITO: Phase II Single-Arm Multi-Center Study of ARRx, the Androgen Receptor Antisense Oligonucleotide Followed by Pembrolizumab Immunotherapy in Metastatic Castration Resistant Prostate Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs IONIS AR 2.5Rx (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ARRO-CITO
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Oct 2018.
- 19 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Feb 2018.